Cero Therapeutics Holdings Files 8-K

TL;DR

Cero Therapeutics filed an 8-K on Sept 10, 2024. Nothing major, just routine filings.

AI Summary

Cero Therapeutics Holdings, Inc. filed an 8-K on September 10, 2024, reporting on other events and financial statements. The company, formerly Phoenix Biotech Acquisition Corp., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing provides an update on Cero Therapeutics' corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain information indicating significant new risks.

Key Players & Entities

• CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
• Phoenix Biotech Acquisition Corp. (company) — Former Company Name
• September 10, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market

Filing Documents

• ea0214146-8k_cerothera.htm (8-K) — 34KB
• 0001213900-24-077366.txt ( ) — 250KB
• cero-20240910.xsd (EX-101.SCH) — 4KB
• cero-20240910_def.xml (EX-101.DEF) — 26KB
• cero-20240910_lab.xml (EX-101.LAB) — 36KB
• cero-20240910_pre.xml (EX-101.PRE) — 25KB
• ea0214146-8k_cerothera_htm.xml (XML) — 6KB

01 Other Events

Item 8.01 Other Events. On September 10, 2024, CERo Therapeutics Holdings, Inc. (the "Company") announced that its special meeting of stockholders (the "Special Meeting") will be postponed from its scheduled time of 12:00 p.m. Eastern Time on September 12, 2024 to 10:00 a.m. Eastern Time on September 19, 2024. The Special Meeting will continue to be held virtually at www.cstproxy.com/cero/2024. There will be no change in the record date for the Special Meeting, which was August 26, 2024. Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the record date can vote, even if they have subsequently sold their shares. Any stockholders who wish to change their vote and need assistance should contact Advantage Proxy, Inc. at 1-877-870-8565, or ksmith@advantageproxy.com. Participants in the Solicitation The Company, and its respective directors and executive officers, and other members of their management and employees, under the rules of the Securities and Exchange Commission ("SEC"), may be deemed participants in the solicitation of proxies of the Company's stockholders in respect of the items of business at the Special Meeting. Information about the directors and executive officers of the Company is set forth in the Company's Definitive Proxy Statement on Schedule 14A relating to the Special Meeting of Stockholders, filed with the SEC on August 26, 2024 and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 2, 2024 and in the Company's other filings with the SEC. Additional information regarding the identity of all potential participants in the solicitation of proxies to the Company's stockholders in connection with the Special Meeting and other matters to be voted upon at the Special Meeting, and their direct and indirect interests, by security holdings or otherwise, is included in the Compa

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Brian G. Atwood Name: Brian G. Atwood Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR